Cocrystal Pharma Receives Pre-IND Responses from the FDA on Oral CC-42344 for Treating Influenza A
Feedback provides greater clarity on regulatory requirements for planned Phase 2b trial BOTHELL, Wash. (March 19, 2024) – Cocrystal Pharma,...
Influenza
